- Species ReactivityHuman
- SpecificityDetects human FCRL5/FcRH5 in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross-reactivity with recombinant human (rh) IRTA3, rhIRTA4, and rhIRTA5 is observed and less than 5% cross-reactivity with rhIRTA1 is observed.
- SourcePolyclonal Goat IgG
- PurificationAntigen Affinity-purified
- ImmunogenMouse myeloma cell line NS0-derived recombinant human FCRL5/FcRH5
Gln16-Arg844
Accession # AAK93971 - FormulationLyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
- LabelUnconjugated
- Western Blot0.1 µg/mLRecombinant Human FCRL5/FcRH5 (Catalog # 2078-FC)
- Flow Cytometry0.25 µg/106 cellsSee below
- CyTOF-readyReady to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
- ReconstitutionReconstitute at 0.2 mg/mL in sterile PBS.
- ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
- Stability & StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
- Davis, R.S. (2007) Annu. Rev. Immunol. 25:525.
- Maltais, L.J. et al. (2006) Nat. Immunol. 7:431.
- Hatzivassiliou, G. et al. (2001) Immunity 14:277.
- SwissProt # Q96RD9.
- Miller, I. et al. (2002) Blood 99:2662.
- Polson, A.G. et al. (2006) Int. Immunol. 18:1363.
- Vidal-Laliena, M. et al. (2005) Cell. Immunol. 236:6.
- Haga, C.L. et al. (2007) Proc. Natl. Acad. Sci. 104:9770.
- Mohan, J. et al. (2006) Blood 107:4433.
- Ise, T. et al. (2005) Clin. Cancer Res. 11:87.
- Ise, T. et al. (2007) Leukemia 21:169.
- Kazemi, T. et al. (2009) Cancer Immunol. Immunother. 58:989.
- Ise, T. et al. (2006) Clin. Chem. Lab. Med. 44:594.
- Davis, R.S. (2007) Annu. Rev. Immunol. 25:525.
- Long Name:Fc Receptor-like 5
- Entrez Gene IDs:83416 (Human); 329693 (Mouse)
- Alternate Names:BXMAS1; BXMAS1MGC119592; CD307; CD307e antigen; CD307e; DKFZp667E2019; DKFZp667F216; Fc receptor homolog 5; Fc receptor-like 5; Fc receptor-like protein 5; FcRH5; FCRH5MGC119593; FCRL5; FcR-like protein 5; FLJ00333; FLJ00397; IFGP5; Immune receptor translocation-associated protein 2; immunoglobulin superfamily receptor translocation associated 2 (IRTA2); IRTA2; IRTA2MGC119590; PRO820
Background:
Fc Receptor-Like 5 (FCRL5), also known as FcRH5, IRTA2, and CD307, is a 120 kDa protein with sequence homology to classical Fc receptors. The type 1 transmembrane FCRL proteins contain from three to nine immunoglobulin-like domains. They are differentially expressed within the B cell lineage and can either promote or inhibit B cell proliferation and activation (1, 2). According to R&D Systems testing, FCRL5 binds to purified human IgG with high affinity. Mature human FCRL5 consists of a 836 amino acid (aa) extracellular domain (ECD) with nine Ig-like domains, a 21 aa transmembrane segment, and a 105 aa cytoplasmic domain with one immunotyrosine activation motif (ITAM) and two immunotyrosine inhibitory motifs (ITIMs) (1, 3). Mouse FCRL5 contains only five Ig-like domains in its ECD. It shares 49% aa sequence identity with human FCRL5 within common regions. Alternate splicing of human FCRL5 generates isoforms that consist of approximately the first one, six, or eight Ig-like domains (3, 4). FCRL5 expression is restricted to mature B lineage cells in lymphoid tissues and blood (3, 5‑7). Its ligation inhibits signaling through the B cell antigen receptor (8). Epstein-Barr virus transformation of B cells induces the up‑regulation of surface FCRL5 by a direct effect of its EBNA2 protein on FCRL5 gene transcription (9). The FCRL5 gene maps to the 1q21 chromosomal locus, a common site of rearrangements in B cell malignancies, and the FCRL5 protein is preferentially expressed in cell lines with 1q21 abnormalities (3). FCRL5 is up‑regulated on tumor cells in some types of B cell malignancies (6, 10‑12). In addition, soluble FCRL5 is elevated in the serum of many B cell leukemia patients (11, 13).
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
如果一个抗体可以用来“做western blot,免疫荧光,免疫共沉淀,ELISA”,我估计着是HRP或碱性磷酸酶或生物素之类标记的,然后需要再加荧光标记的二抗,这类抗体也是不能做流式用的。
我只用过流式的抗体来做免疫荧光(直接染色),效果还不错,但是反过来就没试过。
利用CD3/CD4/IL-17的抗体组合(不同荧光素标记),具体步骤可按照淋巴细胞TH1/2亚型分析的protocol!
一般都是先做CD4的surface staining
然后再做IFN-gamma和IL-17的intrecellular staining
测流式后不用水洗
不用问为什么?_?
英 [ˈfɔ:mæt]美 [ˈfɔ:rmæt]
n. (出版物的)版式;[自](数据安排的)形式;电视节目的总安排(或计划)
vt. 使格式化;安排…的格局;设计…的版面
vi. 设计一个版式

![]()
暂无品牌分类
